Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

Trial Profile

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Planned end date changed from 1 Dec 2020 to 1 Dec 2021.
    • 19 Dec 2017 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
    • 19 Dec 2017 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top